Roivant Says Immunovant Reported Results From Phase 2a Trial Of Batoclimab In Graves' Disease; Says High Dose Batoclimab Achieved 76% Response Rate In Patients Uncontrolled On Antithyroid Drugs At Week 12
Portfolio Pulse from Benzinga Newsdesk
Immunovant reported positive Phase 2a trial results for Batoclimab in Graves' Disease, showing a 76% response rate in patients uncontrolled on antithyroid drugs. The company plans to start a pivotal trial for IMVT-1402 by the end of 2024, with FDA alignment and IND clearance.
September 09, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant's Batoclimab achieved a 76% response rate in a Phase 2a trial for Graves' Disease, indicating strong potential for the drug. The company plans to initiate a pivotal trial for IMVT-1402 by the end of 2024, with FDA alignment and IND clearance.
The positive trial results and upcoming pivotal trial initiation are significant milestones for Immunovant, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Roivant, as a stakeholder in Immunovant, benefits from the positive trial results of Batoclimab in Graves' Disease. The upcoming pivotal trial for IMVT-1402 further strengthens Roivant's investment in Immunovant.
Roivant's stake in Immunovant means it stands to gain from the latter's successful trial results and future developments, likely having a positive impact on Roivant's stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70